Quantitative multimodal retinal imaging

定量多模态视网膜成像

• 批准号: 10211698
• 负责人: Shuliang Jiao
• 金额: $ 50.23万
• 依托单位: FLORIDA INTERNATIONAL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10211698
• 关键词: Address; Age; Age related macular degeneration; Algorithms; Animals; Anterior; Axon; Biological Markers; Clinical; Clinical Research; Clinical Trials; Confocal Microscopy; Cytoskeleton; Data; Degenerative Disorder; Detection; Diagnosis; Disease; Early Diagnosis; Early treatment; Eye; Feedback; Fiber; Fluorescence; Fundus; Glaucoma; Goals; Image; Imaging technology; Individual; Learning; Light; Light Coagulation; Lipofuscin; Mass Spectrum Analysis; Measures; Melanins; Melanosomes; Modeling; Molecular; Monitor; Multimodal Imaging; Nerve Fibers; Nonexudative age-related macular degeneration; Ophthalmologist; Optical Coherence Tomography; Optics; Pathogenesis; Patient Care; Patients; Physiologic Intraocular Pressure; Pigments; Polymethyl Methacrylate; Rattus; Reference Standards; Research; Retinal Degeneration; Retinal Diseases; Retinal Ganglion Cells; Retinal Pigments; Signal Transduction; Slide; Solid; Source; Staging; Stains; Stargardt' s disease; Structure of retinal pigment epithelium; System; Technology; Testing; Theoretical model; Thick; Thinness; Time; Trabecular meshwork structure; Visible Radiation; Work; absorption; age group; animal imaging; attenuation; base; clinically significant; contrast imaging; follow-up; frontier; fundus imaging; human imaging; human subject; imaging study; improved; interest; multimodality; new technology; novel; novel imaging technology; quantitative imaging; retinal damage; retinal imaging; retinal nerve fiber layer; therapy development; titanium dioxide; tool; treatment strategy

Project Summary-Abstract Our ultimate goal is to develop a multimodal VIS-OCT platform for retinal imaging to improve patient care and to advance clinical research. We proposed to develop a visible-light optical coherence tomography (VIS-OCT) platform for multimodal multifunctional imaging of the retina. Two novel VIS-OCT based imaging technologies will be built in this platform: quantitative fundus autofluorescence (FAF) or VIS-OCT-FAF, and retinal nerve fiber layer (RNFL) spectral contrast OCT or DUAL-OCT-RNFL. The two new technologies will add new tools for ophthalmologists to make early diagnosis and better monitor retinal diseases. The proposed work is based on hypotheses that are strongly supported by our theoretical modeling and solid preliminary data. We hypothesize that 1) Quantification of absolute FAF intensity can be achieved by normalizing raw FAF signals with an internal reference and an external standard fluorescence reference; 2) RPE OCT signals simultaneously acquired with FAF can serve as an internal reference; and 3) The spectral contrast of the RNFL can be used as a biomarker for RNFL damage by elevated IOP. Three Specific Aims are proposed. Aim 1: To develop a VIS-OCT platform for VIS-OCT-FAF and DUAL-OCT-RNFL imaging. We will develop and refine the VIS-OCT platform consisting of a VIS-OCT centered at 480 nm, a NIR-OCT centered at 840 nm, and a FAF detection module. A reference target with known fluorescence efficiency and reflectance placed in the intermediate retinal imaging plane will serve as a reference to normalize raw data to obtain absolute FAF intensity and quantitative RNFL spectral reflectance. The reference target will use a PMMA slide stained with A2E as fluorescent molecule. We will introduce the A2E equivalent unit (AEU) as a measure of FAF. Aim 2: To study VIS-OCT-FAF and DUAL-OCT-RNFL imaging in phantom and animals. We will test the system in phantom and animals to verify the capabilities of the VIS-OCT platform, to calibrate and obtain feedback for fine-tuning the hardware and algorithms. Phantom studies will use a model eye with A2E, melanosome and TiO2 to simulate lipofuscin, absorption and scattering in RPE. FAF images from albino and pigmented rats of different ages will be studied. A2E in each imaged eye will be quantified by mass-spectroscopy to verify the accuracy of FAF signals. Elevated IOP will be induced on rats by photocoagulation to the trabecular meshwork. RNFL spectral contrast images from eyes with or without increased IOP will be compared. Aim 3: To study VIS-OCT-FAF and DUAL-OCT-RNFL imaging in human subjects. Our ultimate goal is to develop a multimodal VIS-OCT platform for retinal imaging to improve patient care and to advance clinical research. Studies in this Aim will allow us to learn how the systems behave in a real clinical setting. We will image normal subjects of 6 age groups to establish age-based normative data. Patients with early dry AMD and Stargardt’s disease will also be studied. In the RNFL imaging studies, we will image 6 age groups of normal individuals to establish age-based normative data. Patients with early stage glaucoma will be studied.

项目摘要提取 我们的最终目标是开发一个多模式的Vis-OCT平台，用于视网膜成像，以改善患者护理和对 提前临床研究。我们建议开发可见光光学连贯性层析成像（Vis-OCT） 视网膜多模式多功能成像的平台。两种基于VIS-OCT的新型成像技术 将在此平台中构建：定量底面自动荧光（FAF）或Vis-OCT-FAF，甚至更多的神经纤维 层（RNFL）光谱对比度OCT或双OCT-RNFL。这两种新技术将为 眼科医生进行早期诊断并更好地监测视网膜疾病。拟议的工作是基于 我们的理论建模和固体初步数据强烈支持的假设。我们假设 1）可以通过用一个标准化原始FAF信号来实现绝对FAF强度的量化 内部参考和外标荧光参考； 2）RPE OCT信号 同样，用FAF获取可以作为内部参考； 3）光谱对比度 RNFL可通过升高IOP用作RNFL损害的生物标志物。三个具体目标是 建议的。目标1：开发用于Vis-OCT-FAF和Dual-OCT-RNFL成像的Vis-OCT平台。我们将 开发和完善了由以480 nm为中心的Vis-OCT平台，一个以480 nm为中心的NIR-OCT 840 nm和一个FAF检测模块。具有已知荧光效率和反射率的参考目标 放置在中间残差成像平面中，将作为标准化原始数据以获得绝对数据的参考 FAF强度和定量RNFL光谱反射率。参考目标将使用PMMA幻灯片染色 用A2E作为荧光分子。我们将介绍A2E等效单元（AEU）作为FAF的度量。目标2： 研究幻影和动物中的相关FAF和双OCT-RNFL成像。我们将测试系统 幻影和动物以验证Vis-OCT平台的功能，校准并获得反馈 微调硬件和算法。幻影研究将使用A2E，黑色素体和TiO2的模型眼 为了模拟脂肪霉素，在RPE中滥用和散射。来自白化病和不同大鼠的FAF图像 每只成像的眼睛中的A2E将通过质量光谱量化，以验证 FAF信号。升高的IOP将通过光凝向小梁网诱导大鼠。 RNFL 将比较来自或没有增加IOP的眼睛的光谱对比图像。目标3：学习 人类受试者中的VIS-OCT-FAF和双OCT-RNFL成像。我们的最终目标是开发 用于视网膜成像的多模式Vis-OCT平台，以改善患者护理并推进临床研究。 在此目标中的研究将使我们能够学习系统在实际临床环境中的行为。我们将图像正常 6岁年龄段的受试者建立基于年龄的正常数据。早期干燥AMD和Stargardt的患者 还将研究疾病。在RNFL成像研究中，我们将对6个正常人的6岁年龄段成像 建立基于年龄的正常数据。早期青光眼患者将研究。